Partners
Find out more about the companies that are partnering with the 2nd Annual Personalized Cancer Vaccines Summit. Get in touch if you would like to partner with us in 2025 and learn more about our bespoke sponsorship opportunities.
Lead Partner
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug
discovery and development. Twist is also pursuing longer-term opportunities in biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Expertise Partners
4basebio’s synthetic DNA technology is ideally suited for DNA and mRNA vaccine development and manufacturing. Timelines to large scale and GMP are greatly reduced compared to plasmid DNA, significantly accelerating the development of personalized or rapid response vaccines. Additionally, osDNA™ can be tuned to increase immunostimulatory properties,
facilitating DNA vaccine dose reductions compared to plasmid DNA whilst eliciting an enhanced immune response. And oeDNA™ can be used as IVT template, directly linear and coding long continuous poly(A) tails, providing high yield of homogenous mRNA products.
Almac has been supplying peptides to the research community and for clinical trials for 30 years. The field of personalized cancer vaccines required a new manufacturing paradigm to ensure high-throughput manufacture of multiple neoantigens in an appropriate timescale to the
required quality and regulatory standards. Almac has created a world-leading offering to meet all of those demands, which can be tailored to meet specific client needs. Think Almac for peptide excellence.
Eclipsebio is a private biotechnology company headquartered in San Diego, CA, developing first-in-class technologies and analyses for the development of successful RNA medicines. With the company’s extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, they provide unparalleled support for data-driven characterization and optimization of RNA-based medicines. The company offers its solutions as end-to-end partnerships to help make the RNA medicines of tomorrow achievable today.
Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this
high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics’ technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches
Hosting Partner
Epitopea is a cancer immunotherapeutic company developing accessible off-the-shelf RNA-based immunotherapies. The company has identified novel aberrantly expressed tumor-specific antigens (aeTSA’s) that are hidden in non-canonical DNA, known as CryptigenTM TSAs, using its proprietary CryptoMapTM platform. These hidden CryptigenTM TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal.
Epitopea is backed by a syndicate of leading life science investors.
Exhibition Partners
LineaRx™, an Applied DNA Sciences, Inc. company, delivers enzymatically-produced Linea™ DNA as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity, and scalability to support the next generation of nucleic acid-based therapies. Produced using a proprietary, large-scale polymerase chain reaction (“PCR”) based
manufacturing platform, Linea DNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences.
At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world’s biggest problems in health and sustainability.
Event Partner
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production, and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.